[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633767":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":17,"locations":10,"responsibleParty":23,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Flaxseed",null,[12],"Dietary Supplement: Flaxseed",[14],{"type":15,"name":9,"description":9,"armGroupLabels":16,"otherNames":10},"DIETARY_SUPPLEMENT",[9],[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Chinenye R Dike, MD MS","CONTACT","205 638 9918","cdike@uabmc.edu",{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chinenye Dike","Associate Professor","100633767","omega-3-fatty-acids-in-children-with-sickle-cell-disease-100633767",false,"NCT07530965","OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE","A Single Arm\u002F Open Label Feasibility Trial of Omega-3- Fatty Acids in Children With Sickle Cell Disease","Inclusion Criteria:\n\n\\- Children 5-18 years with SCD at steady state. Steady state will be defined as not requiring an acute care visit for pain in the last 28 days.\n\nExclusion Criteria:\n\n* current use of antibiotics except prophylactic penicillin\n* current use of pre-or probiotic supplements\n* current use of PPI therapy\n* pregnant or lactating females\n* individuals with known allergy to Flaxseed","ALL","5 Years","18 Years",{"count":38,"type":39},20,"ESTIMATED","INTERVENTIONAL",[42],"NA","The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).",[45],"Sickle Cell Disease (SCD)",[47,48,49],"Nutritional trial","sickle cell disease","children","NOT_YET_RECRUITING","2026-04-08",{"date":53,"type":54},"2026-04-15","ACTUAL",{"date":56,"type":39},"2026-06-01",{"date":58,"type":39},"2028-12-31",{"name":5,"class":6}]